This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: ASCO

Celgene is hitting all its numbers and had a great ASCO but the stock is trading near its lows for the year. Doesn't make sense to me, but then big-cap biotech, in general, is so out of favor right now.

In the under-$5 stock category, the best data I saw at ASCO was from Ziopharm Oncology (ZIOP) and its experimental drug palifosfamide in soft-tissue sarcoma. A phase III study is expected to start in the middle of this year.

Thank you, Wilford D.W. III! He emails , "Adam, when people are so negative in their comments towards you, they need to take their negativity somewhere else. The Sunesis Pharmaceuticals (SNSS - Get Report) and Delcath Systems people were particularly vitriolic in their negative comments. Frankly, if I were you, I would not publish any of the demeaning comments directed your way. These small-minded people apparently cannot tolerate any comment that does not extol the virtues of their darling stock.

"People make money when they can objectively evaluate a company. Blind devotion to any company (or any cause for that matter) will cloud any objectivity towards that company. I thought your reporting was even-handed and fair. I appreciate the job you did at the ASCO show and continue to do in your column. My only wish is you would write your column more often."

Don't get personally involved or emotionally connected to your risky biotech stocks! Good advice from Wilford.

@BioRun tweets, "You have dealt with Cell Therapeutic (CTIC - Get Report) nut jobs, Delcathers can't be nearly as bad.

I prefer the term "Delcathians." True words, BioRun, except for this guy:

Stephen K. writes, "Thanks for bleeping all of us shareholders in the Delcath fiasco. You're a real bleeping winner. This isn't the first stock that you have screwed up for me. Is it really worth the money that they pay you to screw over people? I hope someday that I get to meet you in person; see I am dying of cancer and emphysema so it doesn't matter if I go earlier since you just totally bleeped up my finances. You better go and retract all your negative comments on Delcath. I hate you. I am retired military. Bleep you and enjoy my money that you stole through the hedge funds for me."

Sad. No other comment necessary.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
CTIC $1.78 -3.26%
BMY $65.03 -0.44%
CELG $107.54 -2.15%
CLDX $24.30 -3.40%
DCTH $0.88 -5.38%


DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs